Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) Overview | 6 | 1 |
| Therapeutics Development | 7 | 4 |
| T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) Products under Development by Stage of Development | 7 | 1 |
| T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) Products under Development by Therapy Area | 8 | 1 |
| T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) Products under Development by Indication | 9 | 2 |
| T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) Products under Development by Companies | 13 | 2 |
| T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) Therapeutics Assessment | 15 | 6 |
| Assessment by Monotherapy/Combination Products | 15 | 1 |
| Assessment by Mechanism of Action | 16 | 1 |
| Assessment by Route of Administration | 17 | 2 |
| Assessment by Molecule Type | 19 | 2 |
| T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) Companies Involved in Therapeutics Development | 21 | 4 |
| Atox Bio Ltd. | 21 | 1 |
| Bristol-Myers Squibb Company | 22 | 1 |
| OSE Immunotherapeutics | 23 | 1 |
| TheraMAB LLC | 24 | 1 |
| T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) Drug Profiles | 25 | 10 |
| AB-103 Drug Profile | 25 | 3 |
| FR-104 Drug Profile | 28 | 3 |
| lulizumab pegol Drug Profile | 31 | 1 |
| MF-280 Drug Profile | 32 | 1 |
| TAB-08 Drug Profile | 33 | 2 |
| T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) Dormant Projects | 35 | 1 |
| T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) Featured News &Press Releases | 36 | 11 |
| Jun 15, 2016: Atox Bio Awarded Next Milestone-based Option by BARDA to Support Development of AB103 for Necrotizing Soft Tissue Infections | 36 | 1 |
| Dec 07, 2015: Atox Bio Enrolls First Patient in Phase 3 Study of Potential Treatment for Necrotizing Soft Tissue Infection (Flesh Eating Bacteria) | 36 | 1 |
| Jul 09, 2015: Effimune launches Phase I clinical trial on immune system regulation control | 37 | 1 |
| Apr 15, 2015: Effimune obtains regulatory approval for Phase I clinical trial in humans of its new immunomodulator FR104 | 38 | 1 |
| Feb 12, 2015: Two major scientific articles validate Effimune s drug candidate and reinforce the proof of concept of the technology aimed at regulating the immune system | 38 | 1 |
| Dec 25, 2014: TheraMAB presents new clinical data on theralizumab (TAB08) at Nature Biotechnology | 39 | 1 |
| Sep 29, 2014: Atox Bio Awarded Contract Worth up to $24 Million for the Development of AB103 by the Biomedical Advanced Research and Development Authority | 40 | 1 |
| Aug 05, 2014: AB103 Granted Orphan Medicinal Product Designation in the European Union for the Treatment of Necrotizing Soft Tissue Infections | 41 | 1 |
| Jan 14, 2014: TheraMAB announces initiation of Phase II clinical trial of mAb TABO8 for the treatment of Rheumatoid Arthritis | 41 | 1 |
| Apr 09, 2013: Atox Bio Publishes Data Demonstrating Broad Therapeutic Effect Of Flagship Product In Treating Flesh Eating Bacteria | 42 | 1 |
| Nov 20, 2012: Atox Bio Announces Positive Top-line Results In AB103 Necrotizing Soft Tissue Infections Phase IIa Trial | 43 | 1 |
| Sep 10, 2012: Atox Bio s AB103 Receives FDA Fast Track Designation For Treatment Of Necrotizing Soft Tissue Infections | 44 | 1 |
| Nov 15, 2011: TheraMAB launches Phase I clinical trial of first-in-class agonistic monoclonal antibody TAB08 in Russia | 44 | 1 |
| Oct 25, 2011: Atox Bio Receives Orphan Drug Designation For AB103 For Treatment Of Necrotizing Soft Tissue Infections | 45 | 1 |
| May 12, 2011: Atox Bio Completes Phase I clinical study Of AB103 For Severe Bacterial Infections And Sepsis | 46 | 1 |
| Appendix | 47 | 2 |
| Methodology | 47 | 1 |
| Coverage | 47 | 1 |
| Secondary Research | 47 | 1 |
| Primary Research | 47 | 1 |
| Expert Panel Validation | 47 | 1 |
| Contact Us | 47 | 1 |
| Disclaimer | 48 | 1 |